

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018

<https://marketpublishers.com/r/I189BA8EAA6EN.html>

Date: October 2018

Pages: 282

Price: US\$ 2,950.00 (Single User License)

ID: I189BA8EAA6EN

Abstracts

This report can be delivered to the clients within 24 hours

'Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018', report provides comprehensive Insight about pipeline drugs along with technologies involved across this mechanism. The report provides the detailed analysis of 80+ products along with 45+ companies involved. Memgen has been granted Orphan drug designation from US-FDA for ISF 35 for the treatment of stage IIb through IV melanoma.

Products covered by Phase

Phase II and Phase I

Pre-clinical and Discovery

Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Immune Checkpoints Activators

Pipeline analysis of 80+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Immune Checkpoints Activators

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of Immune Checkpoints Activators

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Immune Checkpoints Activators

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling

Pipeline products coverage based on various stages of development ranging from mid stage till discovery stages

Provides pipeline assessment by monotherapy and combination therapy

products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario across Immune Checkpoints Activators to formulate effective R&D strategies

Assess challenges and opportunities that influence Immune Checkpoints Activators R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Immune Checkpoints Activators to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and Insight to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

- Immune Checkpoint Activators Overview
- Rationale for targeting Immune checkpoint Agonist in oncology
- Stimulatory checkpoint molecules
- Advantages of Immune checkpoint Activators
- Constraints of Immune Checkpoint Activators
- Competitive Landscape
- Collaborations and Deal values
- Licensing Opportunities
- Companies Investment Details for Future Development
- Pipeline Therapeutics
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- NKTR-214: Nektar Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- (The list continues)
- Early Stage Products (Phase I)
- Comparative Analysis
- Pre-clinical Stage Products
- Comparative Analysis
- Discovery Stage Products
- Comparative Analysis
- Therapeutic Assessment: Active Products
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Inactive Products
- Comparative Analysis
- Market Drivers and Barriers
- Appendix

List Of Tables

LIST OF TABLES

Table 1: Collaboration and Deal Values for Immune checkpoints Activators, 2017

Table 2: Licensing Opportunities

Table 3: Investment Details

Table 4: Total Products for Immune Checkpoint Activators

Table 5: Mid Stage Products (Phase II)

Table 6: Early Stage Products (Phase I)

Table 7: Pre-clinical Stage Products

Table 8: Discovery Stage Products

Table 9: Assessment by Monotherapy Products

Table 10: Assessment by Route of Administration

Table 11: Assessment by Stage and Route of Administration

Table 12: Assessment by Molecule Type

Table 13: Assessment by Stage and Molecule Type

Table 14: Dormant and Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1: Types of Immune Checkpoint receptors
- Figure 2: Total Products for Immune Checkpoint Activators
- Figure 3: Mid Stage Products (Phase II)
- Figure 4: Early Stage Products (Phase I)
- Figure 5: Pre-clinical Stage Products
- Figure 6: Discovery Stage Products
- Figure 7: Assessment by Monotherapy Products
- Figure 8: Assessment by Route of Administration
- Figure 9: Assessment by Stage and Route of Administration
- Figure 10: Assessment by Molecule Type
- Figure 11: Assessment by Stage and Molecule Type
- Figure 12: Dormant and Discontinued Products

I would like to order

Product name: Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2018

Product link: <https://marketpublishers.com/r/l189BA8EAA6EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l189BA8EAA6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

